1. Scrip
  2. >>Drug Pricing

Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option

 
• By Ian Haydock

“There’s an app for that” could take on added significance under a new alliance for a digital therapeutic for the treatment of depression, in which the partners hope the novel approach will take its place as an effective option among current drug and other cognitive therapies.

Smartphone
Otsuka Teams With Click On Digital Approach To Depression • Source: Shutterstock

Otsuka Pharmaceutical Co. Ltd.’s new alliance with US venture Click Therapeutics Inc. is aimed at developing and commercializing a novel prescription “digital therapeutic” for major depressive disorder, as part of the Japanese firm’s ongoing foray into digital health approaches and strategic focus on the mental health area.

The main goal is to provide an effective new tool to support the management of the highly debilitating condition, one that could be used either as an adjunct to standard drug and other therapy, or potentially by

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.